These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 21080797)

  • 1. Ipilimumab: attenuation of an inhibitory immune checkpoint improves survival in metastatic melanoma.
    Peggs KS; Quezada SA
    Expert Rev Anticancer Ther; 2010 Nov; 10(11):1697-701. PubMed ID: 21080797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer.
    Graziani G; Tentori L; Navarra P
    Pharmacol Res; 2012 Jan; 65(1):9-22. PubMed ID: 21930211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved survival with ipilimumab in patients with metastatic melanoma.
    Hodi FS; O'Day SJ; McDermott DF; Weber RW; Sosman JA; Haanen JB; Gonzalez R; Robert C; Schadendorf D; Hassel JC; Akerley W; van den Eertwegh AJ; Lutzky J; Lorigan P; Vaubel JM; Linette GP; Hogg D; Ottensmeier CH; Lebbé C; Peschel C; Quirt I; Clark JI; Wolchok JD; Weber JS; Tian J; Yellin MJ; Nichol GM; Hoos A; Urba WJ
    N Engl J Med; 2010 Aug; 363(8):711-23. PubMed ID: 20525992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma.
    Lipson EJ; Drake CG
    Clin Cancer Res; 2011 Nov; 17(22):6958-62. PubMed ID: 21900389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Profile of ipilimumab and its role in the treatment of metastatic melanoma.
    Patel SP; Woodman SE
    Drug Des Devel Ther; 2011; 5():489-95. PubMed ID: 22267918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma.
    Weber JS; Kudchadkar RR; Yu B; Gallenstein D; Horak CE; Inzunza HD; Zhao X; Martinez AJ; Wang W; Gibney G; Kroeger J; Eysmans C; Sarnaik AA; Chen YA
    J Clin Oncol; 2013 Dec; 31(34):4311-8. PubMed ID: 24145345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ipilimumab in the treatment of metastatic melanoma: a summary of recent studies.
    Ascierto PA
    Tumori; 2013; 99(6):302e-5e. PubMed ID: 24503809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An immune-active tumor microenvironment favors clinical response to ipilimumab.
    Ji RR; Chasalow SD; Wang L; Hamid O; Schmidt H; Cogswell J; Alaparthy S; Berman D; Jure-Kunkel M; Siemers NO; Jackson JR; Shahabi V
    Cancer Immunol Immunother; 2012 Jul; 61(7):1019-31. PubMed ID: 22146893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ipilimumab in the treatment of melanoma.
    Trinh VA; Hwu WJ
    Expert Opin Biol Ther; 2012 Jun; 12(6):773-82. PubMed ID: 22500861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma.
    Wolchok JD; Hodi FS; Weber JS; Allison JP; Urba WJ; Robert C; O'Day SJ; Hoos A; Humphrey R; Berman DM; Lonberg N; Korman AJ
    Ann N Y Acad Sci; 2013 Jul; 1291(1):1-13. PubMed ID: 23772560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy.
    Hoos A; Ibrahim R; Korman A; Abdallah K; Berman D; Shahabi V; Chin K; Canetta R; Humphrey R
    Semin Oncol; 2010 Oct; 37(5):533-46. PubMed ID: 21074069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The proportion of circulating CD45RO
    Tietze JK; Angelova D; Heppt MV; Reinholz M; Murphy WJ; Spannagl M; Ruzicka T; Berking C
    Eur J Cancer; 2017 Apr; 75():268-279. PubMed ID: 28242504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ipilimumab: in previously treated patients with advanced melanoma.
    Sanford M
    BioDrugs; 2012 Jun; 26(3):185-93. PubMed ID: 22530681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials.
    Wolchok JD; Weber JS; Hamid O; Lebbé C; Maio M; Schadendorf D; de Pril V; Heller K; Chen TT; Ibrahim R; Hoos A; O'Day SJ
    Cancer Immun; 2010 Oct; 10():9. PubMed ID: 20957980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with ipilimumab (MDX-010).
    Weber J
    Oncologist; 2008; 13 Suppl 4():16-25. PubMed ID: 19001147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The ipilimumab lesson in melanoma: achieving long-term survival.
    Delyon J; Maio M; Lebbé C
    Semin Oncol; 2015 Jun; 42(3):387-401. PubMed ID: 25965357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nivolumab: A Review in Advanced Melanoma.
    Scott LJ
    Drugs; 2015 Aug; 75(12):1413-24. PubMed ID: 26220912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ipilimumab: a guide to its use in advanced melanoma.
    Lyseng-Williamson KA; Sanford M
    Am J Clin Dermatol; 2012 Oct; 13(5):349-54. PubMed ID: 22849352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intralesional and systemic immunotherapy for metastatic melanoma.
    Luu C; Khushalani NI; Zager JS
    Expert Opin Biol Ther; 2016 Dec; 16(12):1491-1499. PubMed ID: 27602429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ipilimumab increases activated T cells and enhances humoral immunity in patients with advanced melanoma.
    Weber JS; Hamid O; Chasalow SD; Wu DY; Parker SM; Galbraith S; Gnjatic S; Berman D
    J Immunother; 2012 Jan; 35(1):89-97. PubMed ID: 22130166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.